about
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathwayPoint-of-care outcome assessment in the cancer clinic: audit of data quality.Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.Integrated omic analysis of oropharyngeal carcinomas reveals human papillomavirus (HPV)-dependent regulation of the activator protein 1 (AP-1) pathway.Oral cancer: Current role of radiotherapy and chemotherapy.Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.Primary surgery versus (chemo)radiotherapy in oropharyngeal cancer: the radiation oncologist's and medical oncologist's perspectives.Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma.Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study.Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure.Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients.Imaging and resectability issues of sinonasal tumors.A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy.Novel insights into head and neck cancer using next-generation "omic" technologies.Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience.The "rocky treatment course": identifying a high-risk subgroup of head and neck cancer patients for supportive interventions.Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma.Body mass index and prognosis in patients with head and neck cancer.Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer.Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later.Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy.Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma.Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma.Salvage surgery for locally recurrent oropharyngeal cancer.External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma.Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status.Longer survival in patients with human papillomavirus-related head and neck cancer after positive postradiation planned neck dissection.Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status.Technical challenges of sparing infrahyoid swallowing organs at risk in oropharynx squamous cell cancer treated with IMRT.Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma.Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation.Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer.Extra-pulmonary small cell carcinoma in the head and neck setting: the role of prophylactic cranial irradiation.Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma.
P50
Q28306813-C9EA9C01-0049-4CE9-A87D-5B0672386E62Q33548951-F2E83766-93BD-45ED-AF83-3C24B4E2E733Q34538489-E10217E5-371D-4DF9-99C7-270BD04B42E2Q34635004-1EEC861D-A0F3-432B-B2E9-5A19BA17428DQ34647980-3F23FC5A-BF0F-40E7-A458-35B9830E6DAAQ35558660-B9CB9641-2DDD-4704-8522-3452F9FB2994Q35563379-0EB247E0-E65C-4D23-B693-C4D857EF78A8Q35943671-2BF7A298-8606-4A85-9978-DAC0856E97AAQ36182520-B3D8EF30-78D6-4E91-A0AC-326BB9B6FA14Q36386860-24D34DD6-6813-4B41-A28B-5281D9C8EC91Q37731680-D00FF4BD-7C16-45DD-BAD7-74436E793347Q38053279-072FE707-C29E-4162-95D5-D94A6BD08409Q38071843-C1D8108B-CF11-4CD7-A3C8-24C2C499A92FQ38088001-18E13A39-1C57-4BB5-9206-BEEF6B2E5BC9Q38257116-B57CABB7-6591-477B-B557-1EF439FC9B20Q38318666-158535BB-B14B-4B2E-9310-1E8D25B667D5Q38419382-E41644E0-10DC-47EE-96D3-C41D73463EF7Q38603056-271276A9-0CD8-46D9-A7A3-3C1771C92D71Q38798385-EA637CEA-93E3-4920-B089-5081514BE650Q38807472-20D81E5B-467F-4BB0-8A2E-DA6DE0937FD5Q38890693-1F2DCF0E-2D85-47D1-91B4-C31E929E6A4BQ39209851-94AC9927-65E0-4049-86F8-ACF4C08CD1F5Q40096527-486E1E7F-2850-4D7D-9365-7747CA1B1408Q40308705-64BA84C4-560F-498A-80E2-C10C8D107C75Q40308716-171B89C3-4082-49F8-918D-25E5D8B31DCCQ40308722-2158E841-9BDA-4ACD-BBDF-BEDD00FEBF4AQ40527255-A792077A-42B3-4964-9FA1-505B9C6AFB3FQ40703700-FA49FF0C-7461-451C-AC73-D2B1FF7FABD0Q40839526-1A8281CE-BA0E-4283-A883-0AFB4C381E0FQ41083203-D3C968A6-3CF7-4A54-B7D0-90B80FB57000Q41492192-FA5A6834-7A58-49FA-A2DC-B14028CCCB00Q41692375-7E02B991-429D-4B1C-98F7-F96EC0EA23EEQ42231140-AA782205-1FA8-4BC7-B4E3-4F16896D6591Q42256842-FFFFC096-BFFD-4528-ADDF-FDE2E6C00D28Q43511828-B6C111CE-F24C-4ABB-94CB-9321196B3175Q43540434-B905A301-866F-4078-87D1-CB1BF2F3BBE0Q43618862-D89043D8-99B3-47BF-891D-6092F61491D2Q43665506-F8FF4EA0-209D-45E1-AF95-BFB86E0D08F4Q43812459-14C7DF32-63A4-41AB-A21F-29AAD00F0FB3Q43902595-716F52F1-FDBB-498B-AEBC-8E21257C789B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Shao Hui Huang
@ast
Shao Hui Huang
@en
Shao Hui Huang
@es
Shao Hui Huang
@nl
type
label
Shao Hui Huang
@ast
Shao Hui Huang
@en
Shao Hui Huang
@es
Shao Hui Huang
@nl
prefLabel
Shao Hui Huang
@ast
Shao Hui Huang
@en
Shao Hui Huang
@es
Shao Hui Huang
@nl
P106
P1153
55675093400
P31
P496
0000-0002-8072-4388